Drs Gail Roboz and Pinkal Desai discuss intermediate-risk acute myeloid leukemia.

Relevant disclosures can be found with the episode show notes on Medscape.com (https://www.medscape.com/viewarticle/964532). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals.

Resources

Diagnosis and Management of Acute Myeloid Leukemia in Adults: Recommendations From an International Expert Panel, on Behalf of the European LeukemiaNet https://www.sciencedirect.com/science/article/pii/S0006497120493048?via%3Dihub

Acute Myeloid Leukemia: 2019 Update on Risk-Stratification and Management https://onlinelibrary.wiley.com/doi/full/10.1002/ajh.25214

Gemtuzumab Ozogamicin for De Novo Acute Myeloid Leukemia: Final Efficacy and Safety Updates From the Open-Label, Phase III ALFA-0701 Trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6312010/

Midostaurin Plus Chemotherapy for Acute Myeloid Leukemia With a FLT3 Mutation https://www.nejm.org/doi/full/10.1056/nejmoa1614359

Allogeneic Hematopoietic Stem Cells Transplantation Improves the Survival of Intermediate-Risk Acute Myeloid Leukemia Patients Aged Less Than 60 Years https://link.springer.com/article/10.1007/s00277-018-3584-2

Minimal/Measurable Residual Disease in AML: A Consensus Document From the European LeukemiaNet MRD Working Party https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5865231/?report=printable

Prevention, Recognition, and Management of Adverse Events Associated With Gemtuzumab Ozogamicin Use in Acute Myeloid Leukemia https://jhoonline.biomedcentral.com/articles/10.1186/s13045-020-00975-2

Effective Menin Inhibitor-Based Combinations Against AML With MLL Rearrangement or NPM1 Mutation (NPM1c) https://www.nature.com/articles/s41408-021-00603-3

First in Human Study of KO-539 in Relapsed or Refractory Acute Myeloid Leukemia https://www.clinicaltrials.gov/ct2/show/NCT04067336

A Study of JNJ-75276617 in Participants With Acute Leukemia https://clinicaltrials.gov/ct2/show/NCT04811560

Study of BMF-219, in Adult Patients With Acute Leukemia, Diffuse Large B-Cell Lymphoma and Multiple Myeloma https://clinicaltrials.gov/ct2/show/NCT05153330

A Study of DSP-5336 in Relapsed/Refractory AML/ALL With or Without MLL Rearrangement or NPM1 Mutation https://clinicaltrials.gov/ct2/show/NCT04988555

Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia (AML) in Complete Remission (QUAZAR AML-001) https://clinicaltrials.gov/ct2/show/NCT01757535

Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission https://www.nejm.org/doi/10.1056/NEJMoa2004444

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia https://www.nejm.org/doi/full/10.1056/NEJMoa2012971

Venetoclax Plus LDAC for Newly Diagnosed AML Ineligible for Intensive Chemotherapy: A Phase 3 Randomized Placebo-Controlled Trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290090/

Glasdegib Prescribing Information https://labeling.pfizer.com/ShowLabeling.aspx?format=PDF&id=11336